Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 1, 2012, Pages 33-48

  Tognon, Cristina E ^a   Sorensen, Poul H B ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Cancer; Dependence receptor; Insulin receptor (IR); Insulin like growth factor receptor (IGF1R); IRS proteins; PI3K Akt; Ras MAPK; Targeted therapy; Tyrosine kinase inhibitor (TKI)

Indexed keywords

A 12; ADAPTOR PROTEIN; AVE 1; AVE 1642; BINDING PROTEIN; BMS 536924; BMS 754807; CARBOPLATIN; CIXUTUMUMAB; ERLOTINIB; FIGITUMUMAB; GANITUMAB; GROWTH FACTOR; INSULIN RECEPTOR; LINSITINIB; PACLITAXEL; PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84855885822     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.638626     Document Type: Review

References (137)

1. Bar RS, Peacock ML, Rechler MM, et al. Receptors for multiplication- stimulating activity on human arterial and venous endothelial cells. J Clin Endocrinol Metab 1981;52:814-16 (Pubitemid 13235908)
2. Pollak MN, Perdue JF, Margolese RG, et al. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987;38:223-30 (Pubitemid 18005853)
3. Liu JP, BakerJ, Perkins AS,et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72 (Pubitemid 23306021)
4. Mauro L, Salerno M, Morelli C, et al. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J Cell Physiol 2003;194:108-16 (Pubitemid 36043625)
5. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010;28:4985-95
6. Li YM, Schacher DH, Liu Q, et al. Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 1997;138:362-8 (Pubitemid 27009445)
7. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86 (Pubitemid 46510744)
8. Oates AJ, Schumaker LM, Jenkins SB, et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998;47:269-81 (Pubitemid 28059822)
9. Chappell SA, Walsh T, Walker RA, et al. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br J Cancer 1997;76:1558-61 (Pubitemid 27520581)
10. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009;7:14
11. Chang Q, Li Y, White MF, et al. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res 2002;62:6035-8 (Pubitemid 35244449)
12. Liu YF, Paz K, Herschkovitz A, et al. Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem 2001;276:14459-65
13. Luzi L, Confalonieri S, Di Fiore PP, et al. Evolution of Shc functions from nematode to human. Curr Opin Genet Dev 2000;10:668-74
14. Chuderland D, Seger R. Protein- protein interactions in the regulation of the extracellular signal-regulated kinase. Mol Biotechnol 2005;29:57-74 (Pubitemid 41411094)
15. Giorgetti S, Ballotti R, Kowalski-Chauvel A, et al. The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem 1993;268:7358-64 (Pubitemid 23105629)
16. Moelling K, Schad K, Bosse M, et al. Regulation of Raf-Akt cross-talk. J Biol Chem 2002;277:31099-106 (Pubitemid 34970815)
17. Peruzzi F, Prisco M, Dews M, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19:7203-15 (Pubitemid 29441900)
18. Singleton JR, Dixit VM, Feldman EL. Type 1 insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 1996;271:31791-4 (Pubitemid 26422195)
19. Welsh GI, Miller CM, Loughlin AJ, et al. Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 1998;421:125-30 (Pubitemid 28288076)
20. Pap M, Cooper GM. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway. Mol Cell Biol 2002;22:578-86 (Pubitemid 34027502)
21. Dobashi Y, Watanabe Y, Miwa C, et al. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011;4:476-95
22. Shah OJ, Hunter T. Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol 2006;26:6425-34 (Pubitemid 44277883)
23. Zakikhani M, Blouin MJ, Piura E, et al. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010;123:271-9
24. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1999;19:1346-58 (Pubitemid 29046876)
25. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587-97 (Pubitemid 35177037)
26. Wang J, Riedel H. Insulin-like growth factor-I receptor and insulin receptor association with a Src homology-2 domain-containing putative adapter. J Biol Chem 1998;273:3136-9 (Pubitemid 28109718)
27. Duan C, Yang H, White MF, et al. Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose intolerance. Mol Cell Biol 2004;24:7435-43 (Pubitemid 39121472)
28. Yoshiga D, Sato N, Torisu T, et al. Adaptor protein SH2-B linking receptor-tyrosine kinase and Akt promotes adipocyte differentiation by regulating peroxisome proliferator-activated receptor gamma messenger ribonucleic acid levels. Mol Endocrinol 2007;21:1120-31 (Pubitemid 46984763)
29. Stein EG, Gustafson TA, Hubbard SR. The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors. FEBS Lett 2001;493:106-11 (Pubitemid 32245786)
30. Rajala RV, Chan MD. Identification of a NPXY motif in growth factor receptor-bound protein 14 (Grb14) and its interaction with the phosphotyrosine-binding (PTB) domain of IRS-1. Biochemistry 2005;44:7929-35 (Pubitemid 40776654)
31. Smith FM, Holt LJ, Garfield AS, et al. Mice with a disruption of the imprinted Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during postnatal life. Mol Cell Biol 2007;27:5871-86 (Pubitemid 47257840)
32. Huang Q, Szebenyi DM. Structural basis for the interaction between the growth factor-binding protein GRB10 and the E3 ubiquitin ligase NEDD4. J Biol Chem 2010;285:42130-9
33. Nishida K, Hirano T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci 2003;94:1029-33 (Pubitemid 38035515)
34. Haj FG, Verveer PJ, Squire A, et al. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 2002;295:1708-11 (Pubitemid 34202905)
35. Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem 2003;278:41677-84 (Pubitemid 37310425)
36. Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010;1:1170-7
37. Sekharam M, Nasir A, Kaiser HE, et al. Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res 2003;23(2B):1517-24 (Pubitemid 36754123)
38. Giorgetti-Peraldi S, Peyrade F, Baron V, et al. Involvement of Janus kinases in the insulin signaling pathway. Eur J Biochem 1995;234:656-60
39. Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008;27:1095-105 (Pubitemid 351253178)
40. Monno S, Newman MV, Cook M, et al. Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF-7 breast cancer cells. Endocrinology 2000;141:544-50 (Pubitemid 32250477)
41. Del Valle L, Wang JY, Lassak A, et al. Insulin-like growth factor I receptor signaling system in JC virus T antigen-induced primitive neuroectodermal tumors- medulloblastomas. J Neurovirol 2002;8(Suppl 2):138-47 (Pubitemid 36097791)
42. Tu X, Batta P, Innocent N, et al. Nuclear translocation of insulin receptor substrate-1 by oncogenes and Igf-I. Effect on ribosomal RNA synthesis. J Biol Chem 2002;277:44357-65 (Pubitemid 36157871)
43. Prisco M, Santini F, Baffa R, et al. Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor. J Biol Chem 2002;277:32078-85 (Pubitemid 34969019)
44. Sisci D, Morelli C, Cascio S, et al. The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships. Ann Oncol 2007;18(Suppl 6):vi81-5
45. Lanzino M, Garofalo C, Morelli C, et al. Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells. Breast Cancer Res Treat 2009;115:297-306
46. Sisci D, Morelli C, Garofalo C, et al. Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol 2007;60:633-41 (Pubitemid 46975217)
47. Sun H, Tu X, Prisco M, et al. Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Mol Endocrinol 2003;17:472-86 (Pubitemid 36315640)
48. Wu A, Chen J, Baserga R. Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene 2008;27:397-403
49. Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type 1 insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:485-98
50. Belfiore A, Frasca F, Pandini G, et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623
51. Knowlden JM, Hutcheson IR, Barrow D, et al. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005;146:4609-18 (Pubitemid 41446598)
52. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28 (Pubitemid 41713383)
53. Tauszig-Delamasure S, Bouzas-Rodriguez J. Targeting neurotrophin-3 and its dependence receptor tyrosine kinase receptor C: a new antitumoral strategy. Expert Opin Ther Targets 2011;15:847-58
54. Nikoletopoulou V, Lickert H, Frade JM, et al. Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature 2010;467:59-63
55. Boucher J, Macotela Y, Bezy O, et al. A kinase-independent role for unoccupied insulin and IGF-1 receptors in the control of apoptosis. Sci Signal 2010;3(151):ra87
56. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-7 (Pubitemid 37429826)
57. Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007;26:1636-44 (Pubitemid 46398739)
58. Berns EM, Klijn JG, van Staveren IL, et al. Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 1992;52:1036-9
59. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 2005;9:753-68 (Pubitemid 41131677)
60. Catalogue of somatic mutations in cancer. Cambridge, UK, Wellcome Trust Sanger Insitiute, 2011. Available from: http://www.sanger.ac.uk/genetics/CGP/ cosmic/[Last accessed 4 November 2011]
61. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40 (Pubitemid 46474636)
62. Sachdev P, Jiang YX, Li W, et al. Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J Biol Chem 2001;276:26461-71
63. Wittrock J, Schweizer P, Girgert R. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors. Anticancer Res 2002;22(6C):4205-9
64. Mauro L, Bartucci M, Morelli C, et al. IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem 2001;276:39892-7
65. Long L, Rubin R, Baserga R, et al. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995;55:1006-9
66. Romano G, Prisco M, Zanocco-Marani T, et al. Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. J Cell Biochem 1999;72:294-310 (Pubitemid 29021943)
67. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000;19:5574-81
68. Surmacz E, Sell C, Swantek J, et al. Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor. Exp Cell Res 1995;218:370-80
69. Efstratiadis A. Genetics of mouse growth. Int J Dev Biol 1998;42:955-76 (Pubitemid 28530752)
70. Iritani BM, Eisenman RN. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA 1999;96:13180-5
71. Trumpp A, Refaeli Y, Oskarsson T, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001;414:768-73 (Pubitemid 34000776)
72. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4 (Pubitemid 14106392)
73. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994;14:3604-12 (Pubitemid 24160768)
74. Baker J, Liu JP, Robertson EJ, et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82 (Pubitemid 23306022)
75. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7 (Pubitemid 27527522)
76. Wang W, Kumar P, Epstein J, et al. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 1998;58:4426-33 (Pubitemid 28450047)
77. Liu JL, Blakesley VA, Gutkind JS, et al. The constitutively active mutant Galpha13 transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor. J Biol Chem 1997;272:29438-41
78. Valentinis B, Morrione A, Taylor SJ, et al. Insulin-like growth factor I receptor signaling in transformation by src oncogenes. Mol Cell Biol 1997;17:3744-54 (Pubitemid 27281849)
79. Sun H, Baserga R. The role of insulin receptor substrate-1 in transformation by v-src. J Cell Physiol 2008;215:725-32 (Pubitemid 351632694)
80. Baserga R. The insulin receptor substrate-1: a biomarker for cancer?Exp Cell Res 2009;315:727-32
81. Tognon CE, Martin MJ, Moradian A, et al. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene 2011;published online 1 August 2011; doi:10.1038/onc.2011.323
82. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995;55:249-52
83. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37
84. Potratz JC, Saunders DN, Wai DH, et al. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 2010;70:8770-81
85. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68:8039-48
86. Morrison KB, Tognon C, Garnett MJ, et al. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene 2002;21:5684-95 (Pubitemid 35333001)
87. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4 (Pubitemid 26338048)
88. Cironi L, Riggi N, Provero P, et al. IGF1 is a common target gene of ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008;3:e2634
89. Karnieli E, Werner H, Rauscher FJ III, et al. The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein. J Biol Chem 1996;271:19304-9 (Pubitemid 26271599)
90. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83 (Pubitemid 39014452)
91. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998;18:184-7 (Pubitemid 28082471)
92. Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998;58:5046-8 (Pubitemid 28521157)
93. Tognon C, Garnett M, Kenward E, et al. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res 2001;61:8909-16 (Pubitemid 34013908)
94. Martin MJ, Melnyk N, Pollard M, et al. The insulin-like growth factor I receptor is required for akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 2006;26:1754-69
95. Tognon CE, Somasiri AM, Evdokimova VE, et al. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res 2011;71:1060-70
96. Dias P, Dilling M, Houghton P. The molecular basis of skeletal muscle differentiation. Semin Diagn Pathol 1994;11:3-14 (Pubitemid 24092131)
97. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008;50:799-805 (Pubitemid 351354788)
98. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40 (Pubitemid 46474636)
99. Kolb EA, Gorlick R, Maris JM, et al. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2011;published online 31 May 2011; doi: 10.1002/pbc.23157
100. Kurzrock R, Patnaik A, Aisner J, et al. A Phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010;16:2458-65
101. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7
102. Gualberto A. Figitumumab (CP- 751,871) for cancer therapy. Expert Opin Biol Ther 2010;10:575-85
103. Yanochko GM, Eckhart W. Type 1 insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res 2006;8:R18
104. Salatino M, Schillaci R, Proietti CJ, et al. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type 1 insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 2004;23:5161-74 (Pubitemid 38980349)
105. Carboni JM, Lee AV, Hadsell DL, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005;65:3781-7 (Pubitemid 40616356)
106. Dunn SE, Ehrlich M, Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998;58:3353-61 (Pubitemid 28371076)
107. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32
108. Tamimi RM, Colditz GA, Wang Y, et al. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat 2011;128:243-50
109. Resnik JL, Reichart DB, Huey K, et al. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998;58:1159-64 (Pubitemid 28183203)
110. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:423-9
111. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 2006;11:27-39 (Pubitemid 44309187)
112. Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 2002;8:BR521-6 (Pubitemid 36119174)
113. Haluska P, Carboni JM, TenEyck C, et al. HER receptor signaling confers resistance to the insulin-like growth 112. factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7:2589-98
114. Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008;68:1538-45 (Pubitemid 351346863)
115. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 2009;100:1-8
116. Faivre S, Bouattour M, Raymond E. Novel molecular therapies in hepatocellular carcinoma. Liver Int 2011;31(Suppl 1):151-60
117. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009;1:1153-71
118. Berruti A, Ferrero A, Sperone P, et al. Emerging drugs for adrenocortical carcinoma. Expert Opin Emerg Drugs 2008;13:497-509
119. Maulay V, Middleton MR, Eckhardt SG, et al. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. ASCO; 2010. J Clin Oncol 2010; p.15s
120. Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010;65:765-73
121. Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47 (Pubitemid 46220849)
122. Buck E, Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs 2011;20:605-21
123. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010;16:2512-17
124. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28
125. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials- early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-83
126. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase I expansion cohort study. Lancet Oncol 2010;11:129-35
127. Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol 2010;11:105-6
128. Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15 Suppl):abstr 7500
129. Yap TA, Olmos D, Molife LR, et al. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs 2011;20:1293-304
130. Sachdev D, Singh R, Fujita-Yamaguchi Y, et al. Down-regulation of insulin receptor by antibodies against the type 1 insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006;66:2391-402
131. Schenone S, Brullo C, Musumeci F, et al. ATP-Competitive inhibitors of mTOR: an update. Curr Med Chem 2011;18:2995-3014
132. Martins AS, Ordonez JL, Garcia-Sanchez A, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 2008;68:6260-70
133. Borinstein SC, Barkauskas DA, Krailo M, et al. Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the children's oncology group. Cancer 2011;117:4966-76
134. Yerushalmi R, Gelmon KA, Leung S, et al. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2011;published online 15 May 2011; doi: 10.1007/s10549-011-1529-8
135. Bielen A, Perryman L, Box GM, et al. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRalpha/beta. Mol Cancer Ther 2011;10:1407-18
136. Zhang H, Pelzer AM, Kiang DT, et al. Down-regulation of type 1 insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7 (Pubitemid 46142798)
137. Ulanet DB, Ludwig DL, Kahn CR, et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010;107:10791-8